Albemarle
Compare Albemarle…Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide, including lithium compounds.
SectorsBatteries
Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
AlbemarleAlbemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide, including lithium compounds.
World's largest lithium producer, mining and refining lithium from brine operations in Chile and hard rock in Australia. ~$20B market cap company supplying the critical raw material for virtually all lithium-ion batteries globally. Expanding production capacity to meet surging EV battery demand while navigating volatile lithium commodity prices.
Key Milestones
Founded in Richmond, Virginia by Floyd D. Gottwald Jr. as a spinoff of Ethyl Corporation's specialty chemicals division. Initial product slate: bromine, fire safety chemicals, and pharma intermediates. Lithium becomes a strategic priority only post-2000 as portable electronics drive demand — the 2014 Rockwood acquisition transforms ALB into the world's largest lithium producer.
Albemarle spun out of Ethyl Corporation as standalone NYSE-listed specialty chemicals company under ticker ALB. Initial revenue base ~$700M from bromine and refinery catalysts; lithium contributes <5% of sales. Sets stage for two decades of M&A-driven repositioning toward EV battery materials.
Acquired Akzo Nobel's catalyst business for $799M — heterogeneous-catalyst refining base that would later become a cash-generating segment funding lithium expansion. Strategically signals ALB's shift from commodity bromine to higher-margin specialties.
Acquired Rockwood Holdings for $6.2B (cash + stock) — vaulting Albemarle to the world's largest lithium producer. Rockwood brought Salar de Atacama brine operations in Chile (now ~50% of ALB lithium output), Talison Lithium spodumene JV with Tianqi at Greenbushes Australia, and Kings Mountain (NC) feedstock. Transforms ALB's revenue mix: lithium goes from <10% to >40% of segment EBIT by 2018.
Lithium hydroxide spot prices peaked above $80,000/t (CIF Asia) — driven by Tesla 4680 ramp, BYD Han EV scale-out, China NEV subsidy phase-out demand pull-forward. Albemarle reports Q4 2022 record-quarter EPS of $8.62 (vs $0.43 Q4 2021); full-year 2022 EPS $21.96 vs $1.28 prior year. The lithium boom that funds the 2023 Wodgina expansion and Chester County (SC) site purchase.
Announced $1.3B lithium conversion plant in Chester County, South Carolina — IRA-eligible, targeting 100,000 t/yr battery-grade lithium hydroxide for 2.4M EVs annually. Fed by Kings Mountain (NC) spodumene + Chilean brine. Strategic move to reshore midstream conversion away from China dominance (>70% of global LiOH conversion).
Cut ~4% of workforce (~300 positions) and deferred Kemerton (WA) trains 3/4 commissioning as lithium hydroxide spot prices crashed below $14,000/t — an 85% drawdown from June 2022 peak. Q4 2023 EPS missed by $0.40; capex guide cut $400M. The classic commodity-cycle pivot from boom expansion to contraction.
Halted Kemerton train 3 commissioning and placed train 2 on care and maintenance — additional ~$200M cost-cutting actions. Lithium hydroxide spot at $9,000/t, below ALB's marginal cost from spodumene. Stock down >70% from 2022 peak; CEO Kent Masters under board pressure.
Wodgina spodumene resumed expansion (with JV partner Mineral Resources) as long-dated EV demand outlook firmed — lithium spot stabilizing at $11,500-13,500/t. Capacity restart adds ~50,000 t LCE/yr from train 4 commissioning by 2027. Cautious unwind of 2024 austerity phase.
Reported full-year 2024 EPS of $0.42 (vs $21.96 record in 2022) — confirms cyclical trough, with Q3 2024 quarterly loss the cycle low. Lithium hydroxide spot stabilizing at $13,500/t. Stock recovers ~50% from January 2024 lows on demand-rebound expectations.
Lithium hydroxide spot recovers to $18,000/t in Q1 2026 — first material spot-price uptick since 2022 peak as Chinese inventory cycles bottom. ALB Q1 2026 EPS surprise positive at $0.85 vs consensus $0.30; confirms commodity-cycle inflection.
